PMID: 8581370Oct 1, 1995Paper

In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma

Journal of Hematotherapy
C DemanetK Thielemans

Abstract

We previously reported the successful treatment of the BCL1 lymphoma in Balb/c mice using bispecific (anti-CD3 x anti-idiotype) antibodies (BsAb). The in vivo effect was dependent on the bridging of tumor cells and CD3-positive cells. This direct CD3/TCR cross-linking induced targeted cytolytic and cytotoxic activity toward the tumor cells. Definitive proof of an underlying T cell-mediated mechanism was obtained, as the therapeutic effect was completely lost when animals were T cell depleted before treatment. In all these experiments, animals were injected intraperitoneally (i.p.) with 5000 tumor cells (day 0) and treated with one single intravenous (i.v.) injection of 5 micrograms BsAb (day 9). At a higher tumor load, the therapy lost its effectiveness. We evaluated repeated injections of bispecific antibodies (BsAb) to treat mice with a higher tumor burden (10(5) tumor cells). However, a dose-related immunosuppression (even with 5 micrograms BsAb) was induced. Therefore, this approach was only beneficial if the immune system could recover from the previous injection of BsAb. To prevent this induction of anergy, costimulation with bivalent anti-CD28 has been proposed, but despite the high in vitro T cell proliferation using Bs...Continue Reading

References

Jan 1, 1991·Cellular Immunology·R J DykeF K Stevenson
Jun 1, 1990·Immunology Today·C H JuneC B Thompson
Mar 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·U D Staerz, M J Bevan
Jun 1, 1994·Current Opinion in Immunology·M Croft
Oct 1, 1993·Current Opinion in Immunology·E YefenofJ W Uhr

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.